Anthony C. Tridico Ph.D.
Anthony Tridico is the managing partner of Finnegan’s European office in Brussels, Belgium. He practices all aspects of intellectual property law, from strategic patent portfolio management to litigation.
Dr. Tridico's practice involves diverse technical areas, focusing on pre-litigation analysis and strategic client counseling, due diligence investigations, licensing, patent portfolio management and analysis, prosecution of both U.S. and foreign patent applications, and appeals and oral hearings at the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (PTAB) (formerly the Board of Patent Appeals and Interferences). His litigation practice ranges from protecting the rights of innovative pharmaceutical companies in Abbreviated New Drug Application (ANDA) litigations to defending a client’s right to use diagnostic equipment. He also has vast experience in representing clients in the areas of patent reexamination, including inter partes reexam, reissue, FDA Orange Book listing of patents, and patent term extensions.
Strategic portfolio management and counseling to European clients is an important part of Dr. Tridico's practice. During his previous tenure in Brussels (2001-2004), he gained significant knowledge about the EPC and the diversity of laws and practice among the European national systems. His knowledge of the European legal system and how it differs from the United States allows Dr. Tridico to effectively counsel both European and U.S. clients with global interests in intellectual property.
Dr. Tridico is a frequent lecturer on intellectual property issues at various international programs and conferences targeted to the U.S. and European business community. He is also a regular lecturer on U.S. intellectual property issues at Queen Mary, University of London.
- Adjunct professor at Georgetown University Law School.
- Worked as a research scientist at Brookhaven National Laboratory in Upton, N.Y., with experience in laser systems and investigating surface reactions, nucleation, and crystal structures.
- American Intellectual Property Law Association
- American Chemical Society
- Intellectual Property Owners Association (European Practice Committee, 2012)
- Coauthor. "Personalized Medicine Patents at Risk: Tips for Battling Prometheus and Myriad to Obtain Claims to Diagnostics," CIPA Journal, March 2013.
- Coauthor. "You May Be Entitled to Additional Patent Term: Recent Developments in U.S. Patent Term Adjustment," CIPA Journal, March 2013.
- Coauthor. "IP Update: New Act Correcting The America Invents Act," Westlaw Journal Intellectual Property, Feb. 6, 2013.
- Coauthor. "Protecting Personalized Medicine Inventions," Genetic Engineering & Biotechnology News, Feb. 1, 2013.
- Coauthor. "Avoiding the 'Fiscal Cliff' May Result in Corrections to the America Invents Act that Are More Than 'Technical'," CIPA Journal, Dec. 2012.
- Coauthor. "March Madness: Preparing for the U.S. Transition to a "First-Inventor-to-File' System," CIPA Journal, Dec. 2012.
- Coauthor. "Don't Throw Away Lab Notebooks: Record-Keeping Under AIA," Law360, Nov. 8, 2012.
- Coauthor. "AIA Post-Grant Review and European Oppositions: Will They Work in Tandem, or Rather Pass Like Ships in the Night?" North Carolina Journal of Law & Technology, Fall 2012.
- Coauthor. "It Took Myriad Years to Juxtapose Forethought with Ingenuity and Link BRCA Mutations to Breast Cancer: Will it Take Another Myriad to Settle Rights?" CIPA Journal, Sept. 2012.
- Coauthor. "Like Zeus the Supreme Court Punishes Prometheus: But What Does it all Mean for Patentable Subject Matter?" CIPA Journal, April 2012.